Journal
BIOMATERIALS
Volume 286, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2022.121585
Keywords
Galectin; Lectins; Biomaterial; Inflammation; Drug delivery
Funding
- Science Foundation Ireland
- European Regional Development Fund [13/RC/2073_P2]
- European Union Horizon 2020 Programme (H2020-MSCA-IF-2017) [797716]
- European Union's Horizon 2020 Research and Innovation Programme [713690]
- Marie Curie Actions (MSCA) [797716] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
Galectins, a family of glycan-binding proteins, play a key role in immune cell homeostasis and modulation. Some members of the galectin family are crucial in the resolution of inflammation, while others perpetuate the immune response in a pathological context. They have the potential to be targeted for new therapies, and engineered biomaterials show promise in improving the therapeutic performance of galectin-targeted strategies.
Among all the biological entities involved in the immune response, galectins, a family of glycan-binding proteins, have been described as key in immune cell homeostasis and modulation. More importantly, only some galectin family members are crucial in the resolution of inflammation, while others perpetuate the immune response in a pathological context. As they are expressed in most major diseases, their potential as targets for new therapies seems promising. Most of the galectin family members' ubiquitous expression points to the need for targeted treatments to ensure effectiveness. Engineered biomaterials are emerging as a promising method to improve galectin-targeted strategies' therapeutic performance. In this review, we provide an overview of the role of galectins in health and disease and their potential as therapeutic targets, as well as the state-of-the-art and future directions of galectin-targeted biomaterials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available